ACAT1 and melanoma: Additionally, attaching liposomes loaded with the ACAT1 inhibitor Avasimibe onto T cell surfaces increases membrane cholesterol content, facilitates rapid T cell receptor clustering, and sustains T cell activation, enhancing their cytotoxic effects against glioblastoma and melanoma.